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Members of the B7/CD28 family of immune checkpoints,
such as CTLA4, PD1 and PDL-1, play critical roles in
T cell regulation, and have emerged as promising drug
targets for cancer immunotherapy. We hypothesize that
additional novel members of the B7/CD28 family play a
role as negative immune regulators, and thus may serve
as targets for therapeutic mAbs. Utilizing Compugen’s
predictive discovery platform, we identified eleven novel
proteins that may serve as potential immune checkpoint
candidates. The therapeutic potential of four of these
proteins, CGEN-15001T, CGEN-15022, CGEN-15049
and CGEN-15052, was confirmed following validation of
their immunomodulatory properties and demonstration
of their expression in various cancers. Here we present
results for two of these novel immune checkpoint candi-
dates, CGEN-15049 and CGEN-15052.
A recombinant protein consisting of the extracellular
domain of CGEN-15049 fused to an IgG Fc domain was
shown to inhibit T cell activation and enhance iTregs
differentiation. Moreover, ectopically expressed CGEN-
15049 inhibits activation of melanoma-specific CTLs
and dampens function of NK cells, supporting a role for
this protein in tumor immune modulation. IHC studies
indicate that CGEN-15049 is expressed in the tumor
cells and in the tumor infiltrating immune cells of mul-
tiple epithelial cancers.
CGEN-15052 has demonstrated robust inhibition of
T cell activation in several experimental settings, both
as an ectopically expressed membrane protein and as an
Fc fusion protein. IHC studies indicate that CGEN-
15052 is expressed in multiple epithelial cancers, with
particularly high expression in lung cancer samples.
Taken together, the ability of both of these proteins to
modulate immune response in several types of cells that
play key roles in cancer immune evasion, and their tumor
expression profile, indicate that CGEN-15049 and CGEN-
15052 are potential immune checkpoints that may serve as
targets for cancer immunotherapy.
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